Table 3. Incidence and relative risk of specific SAEs in included trials.
| Specific AEs | Number of studies | RCHOP-14 | RCHOP-21 | Heterogeneity | |||||
|---|---|---|---|---|---|---|---|---|---|
| Pts with SAE/total pts | Pts with SAE/total pts | Relative risk (95% CI) | P value | P value | I2 (%) | ||||
| Neutropenia | 5 | 722/1,340 | 896/1,408 | 0.93 (0.64–1.36) | 0.71 | <0.00001 | 98 | ||
| Thrombocytopenia | 5 | 102/1,340 | 132/1,408 | 0.87 (0.60–1.25) | 0.44 | 0.15 | 41 | ||
| Anemia | 4 | 121/770 | 97/874 | 1.15 (0.88–1.50) | 0.29 | 0.48 | 0 | ||
| Febrile neutropenia | 3 | 103/989 | 134/978 | 0.66 (0.33–1.30) | 0.23 | 0.001 | 85 | ||
| Infection | 4 | 209/1,238 | 225/1,331 | 1.18 (0.72–1.91) | 0.51 | 0.0003 | 84 | ||
| Gastrointestinal toxicity | 4 | 70/1,238 | 74/1,331 | 1.00 (0.73–1.38) | 0.98 | 0.52 | 0 | ||
| Increase in amount of liver enzymes | 3 | 21/521 | 21/521 | 1.04 (0.58–1.86) | 0.9 | 0.99 | 0 | ||
| Cardiac-related | 3 | 15/521 | 14/521 | 1.04 (0.15–7.34) | 0.97 | 0.02 | 74 | ||
| Neurological-related | 3 | 80/989 | 57/978 | 1.41 (0.85–2.33) | 0.18 | 0.19 | 40 | ||
SAE, severe adverse event; AE, adverse event; RCHOP, rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone.